A pooled analysis of four clinical studies of teduglutide (Gattex, Takeda) in children with short bowel syndrome (SBS) revealed no new safety concerns. The findings, presented at the 2019 annual meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (abstract 386), provide further assurances to clinicians who want to use this drug in children.
“Teduglutide is a promising new medication that has really great potential to give our patients better